Genedrive PLC
21 August 2026
21 August 2026
genedrive plc
("genedrive" or the "Company")
Board Appointments
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that Mr Mark Winkler and Mr Mike Fairbourn have agreed to join the Board as independent Non-Executive Directors with effect from 1 September 2026.
The appointments strengthen the Board's financial, strategic, healthcare and commercial expertise as genedrive enters its next phase of growth, focused on scaling adoption of its pharmacogenetic tests in the UK and expanding its international business.
Mark brings extensive financial, strategic and corporate finance experience, advising growth companies, multinational businesses and investors on strategy, finance, governance and growth capital. He is the founder and CEO of Red Earth Advisors and previously held senior roles at Stonehage Fleming and Deloitte where he qualified as an ACA.
Mike brings more than three decades of commercial and leadership experience across the pharmaceutical and medical technology sectors. He spent almost 20 years at global medical technology company Becton Dickinson, including as Vice President and General Manager for the UK and Ireland, and served for ten years on the Board of the Association of British HealthTech Industries ("ABHI"), the UK's leading industry association for health technology, including products such as single use devices, diagnostics and digitally enhanced technologies.
It is proposed that Mark Winkler will chair the Company's Audit and Remuneration Committees.
As previously communicated, Chris Yates, who has served on the Board since 2018, has today stepped down as a Non-Executive Director in order to focus on his other professional commitments.
Mr Graham Cole CBE, Chairman of genedrive plc, said: "Mark and Mike bring highly complementary experience and skills to the Board at an important stage for genedrive as we build on the progress already made and look to further scale the business. Their experience will be invaluable as we focus on broadening adoption of our pharmacogenetic tests, strengthening commercial execution and delivering sustainable growth and value for shareholders.
"On behalf of the Board, I would like to thank Chris for his commitment and significant contribution to genedrive over the past eight years, and for his support during this period of Board transition. We wish him continued success in the future."
Mr Mark Winkler, Non-Executive Director of genedrive plc, said: "genedrive has built a strong foundation and I look forward to working with Graham, Gino and the wider Board, bringing my financial, strategic and governance experience to support disciplined growth and the Company's ambitions as it scales."
Mr Mike Fairbourn, Non-Executive Director of genedrive plc, said: "genedrive has developed innovative pharmacogenetic tests addressing important clinical needs. Having spent much of my career working at the interface between healthcare innovation and clinical practice, I am particularly excited by the opportunity to help broaden adoption and embed these technologies into healthcare pathways in the UK and internationally."
Additional Information on Mark Winkler
The following additional information is provided with regard to the appointment of Mark Alan Winkler, aged 49, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies:
|
|
|
|
Current relevant directorships/partnerships: |
Former relevant directorships/partnerships (within the last five years): |
|
Concise Media Consulting Limited |
Liquidity Media Midco Limited |
|
Liquidity Media Limited |
|
|
Red Earth Advisors Limited |
|
|
4 Sumatra Road Limited |
Mark Winkler does not hold any ordinary shares in the Company.
There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
Additional Information on Mike Fairbourn
The following additional information is provided with regard to the appointment of Michael John Fairbourn, aged 67, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies:
|
|
|
|
Current relevant directorships/partnerships: |
Former relevant directorships/partnerships (within the last five years): |
|
Deko MedTech Oy |
Association of British Healthtech Industries Limited |
|
Fairbourn Consulting Limited |
Becton Dickinson Holdings Designated Activity Company |
|
Becton, Dickinson U.K. Limited |
Mike Fairbourn does not hold any ordinary shares in the Company.
There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
|
genedrive plc |
+44 (0)161 989 0245
|
|
Gino Miele: CEO / Russ Shaw: CFO |
|
|
Peel Hunt LLP (Nominated Adviser and Broker) |
+44 (0)20 7418 8900 |
|
James Steel |
|
|
5654 & Company (Media & Investor Relations) |
genedrive@5654.co.uk |
|
Matthew Neal |
+44 (0)7917 800 011 |
|
Melissa Gardiner |
+44 (0)7757 697357 |
Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
About genedrive plc (http://www.genedrive.com).
genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.
genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention
The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.
Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.